五和博澳冲刺港交所：聚焦代谢病及肿瘤治疗，中国首个原创控血糖天然药物已上市

Core Viewpoint - Beijing Wuhua Boao Pharmaceutical Co., Ltd. (Wuhua Boao) is preparing for an IPO on the Hong Kong Stock Exchange, focusing on innovative natural drugs for treating metabolic diseases and cancers, with a valuation of 4.038 billion yuan prior to the IPO [2][11]. Company Overview - Wuhua Boao was established in 2010 and specializes in high-barrier innovative drug research and development, industrialization, and commercialization, particularly targeting major diseases such as metabolic disorders and malignant tumors [3]. - The company has developed a drug delivery system (DDS) aimed at overcoming technical bottlenecks in drug delivery [3]. Key Products - The core product "Sangbongen®" (WH001) is a Class 1 innovative traditional Chinese medicine approved for market in March 2020, recognized as China's first and only approved natural drug for blood sugar control, and also the world's first plant-derived effective component for lowering blood sugar [3]. - Wuhua Boao is expanding its treatment indications from diabetes to include obesity, MASH, and PCOS, aiming to provide systematic treatment capabilities for complex metabolic diseases [4]. Research and Development Pipeline - The company has eight drug candidates in development, including three core products: WH007, WH006, and WH002 [4]. - WH007 is a Class 2.3 modified new drug for treating polycystic ovary syndrome (PCOS), currently the only natural drug in clinical development for PCOS in China, with Phase II trials approved to start in December 2025 [7]. - WH006 is a Class 2.3 modified new drug for adult obesity, with Phase II clinical trials initiated in August 2025, also the only natural drug in clinical Phase II for obesity in China [8]. - WH002 is a targeted lipid emulsion for treating Luminal breast cancer, with Phase II trials expected to complete in November 2025 and Phase III trials anticipated to start in 2026 [9]. Financial Performance - For the fiscal year 2024 and the nine months ending September 30, 2025, Wuhua Boao reported revenues of 208 million yuan and 207 million yuan, respectively, with gross margins of 72.1% and 74.1% [10]. - The adjusted net losses for the same periods were 88.81 million yuan and 36.85 million yuan, indicating a narrowing loss margin [10].